BCL2 and Miyoshi myopathy: The overexpression of Bcl-2 is almost universal in MM cell lines and primary patient samples and promotes inappropriate survival leading to resistance to therapy with interferon, dexamethasone, etoposide, doxorubicin and bortezomib[22], [23], [24], [25].